3.12
0.20 (6.68%)
| Previous Close | 2.92 |
| Open | 3.04 |
| Volume | 911,101 |
| Avg. Volume (3M) | 1,398,132 |
| Market Cap | 428,589,696 |
| Price / Sales | 321.64 |
| Price / Book | 2.20 |
| 52 Weeks Range |
| Operating Margin (TTM) | -6,661.77% |
| Diluted EPS (TTM) | -0.360 |
| Total Debt/Equity (MRQ) | 5.30% |
| Current Ratio (MRQ) | 14.96 |
| Operating Cash Flow (TTM) | -44.85 M |
| Levered Free Cash Flow (TTM) | -27.80 M |
| Return on Assets (TTM) | -23.81% |
| Return on Equity (TTM) | -36.07% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Compass Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 18.08% |
| % Held by Institutions | 70.99% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 32.00 (D. Boral Capital, 927.29%) | Buy |
| Median | 11.00 (253.13%) | |
| Low | 6.00 (Leerink Partners, 92.62%) | Buy |
| Average | 13.33 (327.93%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 2.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 02 Apr 2025 | 12.00 (285.23%) | Buy | 1.99 |
| 24 Feb 2025 | 12.00 (285.23%) | Buy | 3.11 | |
| Leerink Partners | 02 Apr 2025 | 6.00 (92.62%) | Buy | 1.99 |
| D. Boral Capital | 01 Apr 2025 | 32.00 (927.29%) | Buy | 1.99 |
| 27 Feb 2025 | 32.00 (927.29%) | Buy | 2.92 | |
| Piper Sandler | 19 Feb 2025 | 12.00 (285.23%) | Buy | 3.38 |
| Jefferies | 10 Feb 2025 | 8.00 (156.82%) | Buy | 3.90 |
| HC Wainwright & Co. | 10 Jan 2025 | 10.00 (221.03%) | Buy | 1.77 |
| 08 Jan 2025 | 10.00 (221.03%) | Buy | 1.86 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Apr 2025 | Announcement | Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum |
| 01 Apr 2025 | Announcement | Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer |
| 31 Mar 2025 | Announcement | Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer |
| 27 Feb 2025 | Announcement | Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update |
| 29 Jan 2025 | Announcement | Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference |
| 08 Jan 2025 | Announcement | Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |